SlideShare ist ein Scribd-Unternehmen logo
1 von 25
Downloaden Sie, um offline zu lesen
8th July 2008
Living Longer – At What Price?
Mortality Modelling
Contents
Mortality Modelling
Contents
Deterministic Mortality Models
Deterministic Models 3
Stochastic Mortality Models
Why Stochastic Models? 6
Stochastic Mortality Models 9
Application Procedure and Model Comparison 15
Appendix 22
2
“Where there is a considerable range of possible outcomes, the FSA expects firms to use
stochastic techniques to evaluate these risks. In time, for example, longevity risk, where this
constitutes a significant risk for the firm, may fall into this category.”
-----FSA’s Regulatory Guidance for Actuaries
Mortality Modelling
Deterministic Mortality Models
3
Mortality Modelling
Deterministic Projections
Scenario Tests with Different Deterministic Mortality Tables
 Different mortality assumptions imply different pension benefit cash flow structures for a
specific pension scheme.
 This research compares the impact on a specific pension scheme’s cash flows, presents
value and duration of ten deterministic mortality projections produced by the CMI,
including the original “92” Series projection, cohort projections and cohort projection with
1% and 2% underpins.
4
 The table below shows that a change in mortality assumptions can have a big impact on
the PV and Duration of a pension scheme’s benefits.
*E.g. The PV for this specific scheme (calculated with a long cohort / 2% underpin mortality
table) is 13% larger than the PV calculated with “92” table, and the duration increases by
13.5%.
Scenario Tests with Different Deterministic Mortality Tables
Active Deferred Pensioners Total
PV
(£ million)
Duration
(year)
PV
(£ million)
Duration
(year)
PV
(£ million)
Duration
(year)
PV
(£ million)
Duration
(year)
"92" 195 26.8 195 25.5 598 11.1 988 17.0
SC 196 26.9 197 25.6 605 11.2 998 17.1
SC 1% 201 27.5 201 26.1 613 11.4 1,015 17.5
SC 2% 216 29.3 218 27.8 641 12.3 1,075 18.9
MC 200 27.2 201 25.9 619 11.4 1,020 17.4
MC 1% 204 27.8 205 26.4 626 11.6 1,035 17.7
MC 2% 218 29.4 220 27.9 648 12.4 1,086 18.9
LC 209 28.0 210 26.6 648 12.0 1,067 18.0
LC 1% 212 28.5 214 27.1 652 12.2 1,078 18.3
LC 2% 223 29.8 225 28.3 666 12.7 1,115 19.3
5
Accounting
basis
TPR new
proposal
Mortality Modelling
Deterministic Projections
Mortality Modelling
Why Stochastic Models?
Projection vs. Experience : How projections can go wrong (CMI Lee-Carter Projection)
Source: CMI Male Assured Lives
6
 By using Male Assured Lives data from 1947 to 1980 to project the future mortality rate from 1980
to 2004 at age 65.
 The graph shows that, by the end of 2004, the projected probability of death for males aged 65 is
about 0.015, but the realised mortality rate is about 0.009 - which is much lower than predicted.
 What is worse is that projections continually overestimate the probability of death over the
estimation period; in other words, they underestimate the life expectancy substantially.
Graduation: Smoothing Raw Data to Remove Random Fluctuation
Source: CMI Male Assured Lives 1947-2005
Raw Death Rate Graduated Death Rate
In order to calculate the PV of liabilities, an actuarial valuation requires best estimate mortality rates
as a starting point, even if a prudent margin is being added, to evaluate liability present values; these
will be an instruction to set contribution rate as well. But we will never know when mortality
experience will go wrong and how far it may be from the “so-called” best estimates. These best
estimates are based on “smoothed” results - which means the randomness in mortality is largely
ignored.
7
Mortality Modelling
Why Stochastic Models
Stochastic Projections:
Allow for randomness in mortality rates
Can estimate Longevity Value at Risk (LVaR)
•Monte-Carlo Simulation:
Can show the whole range of possible future mortality rates
•Probability of each scenario
•Full distribution of future pension liabilities
Deterministic Projections:
Assume fixed mortality rates
Scenario Tests:
Cannot determine the probability of a specific scenario
•Single Value of Liability: Does not include all scenarios
• Does not show full distribution of possible future mortality
rates
Compare Deterministic and Stochastic Mortality Models
8
Mortality Modelling
Why Stochastic Models
Mortality Modelling
Stochastic Mortality Models
9
Mortality Modelling
Stochastic Mortality Models
Eight Stochastic Mortality Models
10
Details of model specifications are described in Redington Longevity Technical paper, which is available upon request.
All models capture the age and period effects but they vary in the modelling approach.
Lee-Carter extension, APC, Three factor CBD, Three-factor CBD extension and Four-Factor CBD capture
the cohort effect in the model. (2, 6, 7 and 8)
1
2
3
4
5
6
7
8
Two Major Model Families
 CBD Models: The Cairns, Blake and Dowd (CBD) model was developed by three professors in
the UK: Professor David Blake from Cass Business School, Professor Andrew Cairns from Heriot-
Watt University and Professor Kevin Dowd from Nottingham University Business School. The
CBD model was developed for and tested using mortality data from males living in England and
Wales, and has yet to be tested with data from any other countries. However, the model has
already been taken up widely by actuaries in Germany and is currently being investigated by
the CMI (Pension Institute, 2007).
 Lee Carter Models: The Lee-Carter model was developed by Professors Ronald Lee and
Lawrence Carter. This model has become the “leading statistical model of mortality
forecasting in the demographic literature” in the United States (Deaton and Paxson, 2004). Lee
and Carter originally calibrated their model to use United States mortality data from 1933-
1987. Girosi and King (2007) note that the model is “now being applied to all-cause and cause-
specific mortality data from many countries and time periods, and all well beyond the
application for which it was designed” (Girosi and King, 2007).
11
Mortality Modelling
Stochastic Mortality Models
Two Major Model Families
 Four models from the two major model families, the CBD and Lee-Carter, were tested.
 Lee Carter Model: A simple one-factor model that assumes mortality improvement for
different ages has a perfect correlation. As a result, the model gives less flexibility in age
specific volatilities and usually projects less volatile future mortality rates.
 CBD Model: Accounts for more factors to allow different improvements across different
ages at different periods of time. As a result, the model gives more flexibility in age specific
volatilities and often projects more volatile future mortality rates than Lee Carter model.
12
Mortality Modelling
Stochastic Mortality Models
Data Sample:
 The data used in testing the four models was taken from the Human Mortality Database (HMD).
 In order to analyse the models’ sensitivities to the choice of data sample, models were calibrated
and tested against two samples:
 The first sample included population mortality data for ages 20 to 100 from 1920 to 1960;
 The second test included population mortality data for ages 20 to 100 from 1963 to 1983;
 The figures below show mortality rate data in the first sample is more volatile than the mortality
rate data in the second sample.
13
Mortality Modelling
Stochastic Mortality Models
Summary of Statistical Tests
Statistical tests: MSE, Sign and Outlier Test
• MSE and Sign Test show that the forecasting accuracy of CBD family models is more sensitive
to the choice of sample than Lee Carter family.
• The Outlier test shows that both of the models fail to capture the “hump” effect for younger
ages, and the Lee-Carter models also systematically over-estimated the mortality rates for
old ages and failed to project a proper confidence interval for old ages statistically.
Conclusion
The Two-Factor CBD model is the most appropriate model for longevity risk analysis and
management purpose, because it:
 Produces stabler projections of future mortality rates;
 Produces confidence intervals that cover most realised mortality rates, especially for older
ages;
 Is easy to implement.
14
Mortality Modelling
Stochastic Mortality Models
Mortality Modelling
Application of Stochastic Mortality Models
15
Application Procedures
Evaluate possible solutions
Manage longevity risk in the overall LDI strategy
Quantify longevity risk
Estimate benefit cash flows with simulated mortality rates
Generate simulations on future mortality rates with calibrated model
Calibrate mortality model with historical data
16
Mortality Modelling
Applications
Stochastic Simulations – Mortality Rate
• By calibrating stochastic mortality models with historical data, a large number of simulated
mortality tables can be generated (e.g. 1000 tables).
• These simulated mortality tables provide a range of possible future mortality rates by incorporating
age, period and cohort effects.
• The two graphs below show the range of mortality rate simulations and a comparison with the
realised mortality rate during that period.
17
Mortality Modelling
Applications
Stochastic Cash Flows
For a better understanding of pension liability, cashflow analysis is largely adopted:
 By using the simulated future mortality rates from previous simulations, the cashflow
structure of a generic pension scheme is projected for 1000 times.
 By doing this, we can observe a range of possible cash flows implied by the two models.
 This forms the basis of quantifying longevity risk for a specific pension scheme.
CBD Model Lee Carter Model
18
Mortality Modelling
Applications
 The cashflow structures are then discounted with a flat discount curve. The two graphs
below show the distribution of pension liabilities under the different projections of the
two models.
 CBD Model: Predicts a smoother and more spread out distribution of liabilities. This means
more longevity risk on the tails.
 Lee Carter Model: Predicts a tighter distribution of pension liabilities. This means less
longevity risk on the tails.
Model Comparison - Distributions
19
Mortality Modelling
Applications
Model Comparison – Main Statistics
Two- Factor CBD Model Lee Carter Model
Two-Factor CBD Model PV Lee-Carter Model PV Short cohort Medium cohort Long cohort
(£’000,000) (£’000,000) (£’000,000) (£’000,000) (£’000,000)
Mean 1,002 998 998 1,020 1,067
S.d. 32 16 n/a n/a n/a
95% 1,054 1,026 n/a n/a n/a
5% 954 973 n/a n/a n/a
VaLR 52 27 n/a n/a n/a
As % of Total Liability 5.17% 2.73% n/a n/a n/a
20
Mortality Modelling
Applications
Contacts
Dawid Konotey-Ahulu | Partner Direct: +44 (0) 207 250 3415
dawid@redingtonpartners.com
Robert Gardner | Partner Direct: +44 (0) 207 250 3416
robert.gardner@redingtonpartners.com
Redington Partners LLP
13 -15 Mallow Street London EC1Y 8RD
Telephone: +44 (0) 207 250 3331
www.redingtonpartners.com
THE DESTINATION FOR ASSET & LIABILITY MANAGEMENT
Contacts
Disclaimer
Disclaimer For professional investors only. Not suitable for private customers.
The information herein was obtained from various sources. We do not guarantee every aspect of its accuracy. The information is for your private information and is for discussion
purposes only. A variety of market factors and assumptions may affect this analysis, and this analysis does not reflect all possible loss scenarios. There is no certainty that the
parameters and assumptions used in this analysis can be duplicated with actual trades. Any historical exchange rates, interest rates or other reference rates or prices which appear
above are not necessarily indicative of future exchange rates, interest rates, or other reference rates or prices. Neither the information, recommendations or opinions expressed
herein constitutes an offer to buy or sell any securities, futures, options, or investment products on your behalf. Unless otherwise stated, any pricing information in this message is
indicative only, is subject to change and is not an offer to transact. Where relevant, the price quoted is exclusive of tax and delivery costs. Any reference to the terms of executed
transactions should be treated as preliminary and subject to further due diligence .
Please note, the accurate calculation of the liability profile used as the basis for implementing any capital markets transactions is the sole responsibility of the Trustees' actuarial
advisors. Redington Partners will estimate the liabilities if required but will not be held responsible for any loss or damage howsoever sustained as a result of inaccuracies in that
estimation. Additionally, the client recognizes that Redington Partners does not owe any party a duty of care in this respect.
Redington Partners are investment consultants regulated by the Financial Services Authority. We do not advise on all implications of the transactions described herein. This
information is for discussion purposes and prior to undertaking any trade, you should also discuss with your professional tax, accounting and / or other relevant advisers how
such particular trade(s) affect you. All analysis (whether in respect of tax, accounting, law or of any other nature), should be treated as illustrative only and not relied upon as
accurate.
21
Appendix
Model Testing
Evaluation Criteria
 Mean Squared Error (MSE)
MSE is used to test the forecasting accuracy of the models defined as:
Where T is the total number of projected years, and are respectively the projected and actual
observation for age x at time i. The smaller the test statistic is the more accurate the projection is.
 Sign Test
Sign test is used to test the hypothesis that the model residuals are unbiased. Mathematically, if m is the
number of positive residuals, then m should follow a binomial distribution with parameters being the
number of residuals (n) and 0.5. For test here, normal approximation is used.
 Outlier Test
The outliers test is used to study the model’s capability to project confidence intervals which can cover
most of the realized mortality rates as expected. For example, a 90% confidence interval is expected to
cover 90% of the observation points.
22
MSE and Sign Test
 MSE test shows that, in the 40 year data sample, the Lee-Carter model provides the best
projection accuracy; however, in the 20 year data sample, the CBD models performed better than
the Lee Carter models, while the three-factor CBD model provided the most accurate results.
 Comparing the sign test results reveals that nearly all models based on two datasets predict
biased mortality rates; this is because the sign test statistics are all significantly larger than the
critical value of 1.96. The exception is the three-factor CBD model in the 40 year sample data
test.
 In general, the two tests show that the forecasting accuracy for CBD family models is more
sensitive to the choice of sample than Lee Carter family. MSE test statistics show that the CBD
models can produce a better projection if the end-user properly selects the sample space.
23
Appendix
Model Testing
Outliers Test
 The tables above show that, for both projection periods, the number of outliers is
greater than expected. The exception is the two-factor CBD model, which
produced significantly less outliers than expected.
24
Appendix
Model Testing
Outliers Test
 The orange area represents outlier in right hand tail; the red area represents outlier in left
hand tail, and the green area represents observations that are within the confidence
interval.
 The test results show that both of the models failed to capture the “hump” effect for
younger ages. The Lee-Carter models also systematically over-estimated the mortality rates
for old ages and failed to project a proper confidence interval for old ages.
CBD ModelLee Carter Model
25
Appendix
Model Testing

Weitere ähnliche Inhalte

Ähnlich wie Living Longer At What Price- Mortality Modelling

Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
Quantifying the Uncertainty of Long-Term Economic Projections
Quantifying the Uncertainty of Long-Term Economic ProjectionsQuantifying the Uncertainty of Long-Term Economic Projections
Quantifying the Uncertainty of Long-Term Economic ProjectionsCongressional Budget Office
 
MSc paper Jekaterina Pasecnika-The University of Southampton(preview)
MSc paper Jekaterina Pasecnika-The University of Southampton(preview)MSc paper Jekaterina Pasecnika-The University of Southampton(preview)
MSc paper Jekaterina Pasecnika-The University of Southampton(preview)Katerina (Kat) Pasecnika
 
chain leader
chain leaderchain leader
chain leadermarhadi .
 
Longevity Risk in Fair Valuing Level-Three Assets in Securitized Portfolios -...
Longevity Risk in Fair Valuing Level-Three Assets in Securitized Portfolios -...Longevity Risk in Fair Valuing Level-Three Assets in Securitized Portfolios -...
Longevity Risk in Fair Valuing Level-Three Assets in Securitized Portfolios -...Peter Mazonas
 
Machine Learning for Survival Analysis
Machine Learning for Survival AnalysisMachine Learning for Survival Analysis
Machine Learning for Survival AnalysisChandan Reddy
 
Modelling Credit Risk of Portfolios of Consumer Loans
Modelling Credit Risk of Portfolios of Consumer LoansModelling Credit Risk of Portfolios of Consumer Loans
Modelling Credit Risk of Portfolios of Consumer LoansMadhur Malik
 
IRJET- Analysis of Automated Detection of WBC Cancer Diseases in Biomedical P...
IRJET- Analysis of Automated Detection of WBC Cancer Diseases in Biomedical P...IRJET- Analysis of Automated Detection of WBC Cancer Diseases in Biomedical P...
IRJET- Analysis of Automated Detection of WBC Cancer Diseases in Biomedical P...IRJET Journal
 
Developing and validating statistical models for clinical prediction and prog...
Developing and validating statistical models for clinical prediction and prog...Developing and validating statistical models for clinical prediction and prog...
Developing and validating statistical models for clinical prediction and prog...Evangelos Kritsotakis
 
Presentation to CCG - Capita Health Freakononics v3
Presentation to CCG - Capita Health Freakononics v3Presentation to CCG - Capita Health Freakononics v3
Presentation to CCG - Capita Health Freakononics v3Mike Thorogood
 
Selection of Research Material relating to RiskMetrics Group CDO Manager
Selection of Research Material relating to RiskMetrics Group CDO ManagerSelection of Research Material relating to RiskMetrics Group CDO Manager
Selection of Research Material relating to RiskMetrics Group CDO Managerquantfinance
 
Estimating ambiguity preferences and perceptions in multiple prior models: Ev...
Estimating ambiguity preferences and perceptions in multiple prior models: Ev...Estimating ambiguity preferences and perceptions in multiple prior models: Ev...
Estimating ambiguity preferences and perceptions in multiple prior models: Ev...Nicha Tatsaneeyapan
 
Multimorbidity Multistate Model
Multimorbidity Multistate ModelMultimorbidity Multistate Model
Multimorbidity Multistate Modeljmanali1996
 
MIRA Risk Review: Multivariate metabolic risk calculator
MIRA Risk Review: Multivariate metabolic risk calculatorMIRA Risk Review: Multivariate metabolic risk calculator
MIRA Risk Review: Multivariate metabolic risk calculatorMunich Re
 
ISCB 2023 Sources of uncertainty b.pptx
ISCB 2023 Sources of uncertainty b.pptxISCB 2023 Sources of uncertainty b.pptx
ISCB 2023 Sources of uncertainty b.pptxBenVanCalster
 

Ähnlich wie Living Longer At What Price- Mortality Modelling (20)

Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Quantifying the Uncertainty of Long-Term Economic Projections
Quantifying the Uncertainty of Long-Term Economic ProjectionsQuantifying the Uncertainty of Long-Term Economic Projections
Quantifying the Uncertainty of Long-Term Economic Projections
 
MSc paper Jekaterina Pasecnika-The University of Southampton(preview)
MSc paper Jekaterina Pasecnika-The University of Southampton(preview)MSc paper Jekaterina Pasecnika-The University of Southampton(preview)
MSc paper Jekaterina Pasecnika-The University of Southampton(preview)
 
chain leader
chain leaderchain leader
chain leader
 
Longevity Risk in Fair Valuing Level-Three Assets in Securitized Portfolios -...
Longevity Risk in Fair Valuing Level-Three Assets in Securitized Portfolios -...Longevity Risk in Fair Valuing Level-Three Assets in Securitized Portfolios -...
Longevity Risk in Fair Valuing Level-Three Assets in Securitized Portfolios -...
 
Machine Learning for Survival Analysis
Machine Learning for Survival AnalysisMachine Learning for Survival Analysis
Machine Learning for Survival Analysis
 
Modelling Credit Risk of Portfolios of Consumer Loans
Modelling Credit Risk of Portfolios of Consumer LoansModelling Credit Risk of Portfolios of Consumer Loans
Modelling Credit Risk of Portfolios of Consumer Loans
 
Ph.D Day presentation
Ph.D Day presentationPh.D Day presentation
Ph.D Day presentation
 
IRJET- Analysis of Automated Detection of WBC Cancer Diseases in Biomedical P...
IRJET- Analysis of Automated Detection of WBC Cancer Diseases in Biomedical P...IRJET- Analysis of Automated Detection of WBC Cancer Diseases in Biomedical P...
IRJET- Analysis of Automated Detection of WBC Cancer Diseases in Biomedical P...
 
ESTIMATING R 2 SHRINKAGE IN REGRESSION
ESTIMATING R 2 SHRINKAGE IN REGRESSIONESTIMATING R 2 SHRINKAGE IN REGRESSION
ESTIMATING R 2 SHRINKAGE IN REGRESSION
 
Developing and validating statistical models for clinical prediction and prog...
Developing and validating statistical models for clinical prediction and prog...Developing and validating statistical models for clinical prediction and prog...
Developing and validating statistical models for clinical prediction and prog...
 
Presentation to CCG - Capita Health Freakononics v3
Presentation to CCG - Capita Health Freakononics v3Presentation to CCG - Capita Health Freakononics v3
Presentation to CCG - Capita Health Freakononics v3
 
Selection of Research Material relating to RiskMetrics Group CDO Manager
Selection of Research Material relating to RiskMetrics Group CDO ManagerSelection of Research Material relating to RiskMetrics Group CDO Manager
Selection of Research Material relating to RiskMetrics Group CDO Manager
 
Estimating ambiguity preferences and perceptions in multiple prior models: Ev...
Estimating ambiguity preferences and perceptions in multiple prior models: Ev...Estimating ambiguity preferences and perceptions in multiple prior models: Ev...
Estimating ambiguity preferences and perceptions in multiple prior models: Ev...
 
Multimorbidity Multistate Model
Multimorbidity Multistate ModelMultimorbidity Multistate Model
Multimorbidity Multistate Model
 
MIRA Risk Review: Multivariate metabolic risk calculator
MIRA Risk Review: Multivariate metabolic risk calculatorMIRA Risk Review: Multivariate metabolic risk calculator
MIRA Risk Review: Multivariate metabolic risk calculator
 
Trends in mortality_v0.9
Trends in mortality_v0.9Trends in mortality_v0.9
Trends in mortality_v0.9
 
ISCB 2023 Sources of uncertainty b.pptx
ISCB 2023 Sources of uncertainty b.pptxISCB 2023 Sources of uncertainty b.pptx
ISCB 2023 Sources of uncertainty b.pptx
 
Afs 2016-certainty of lifestyle shared
Afs 2016-certainty of lifestyle sharedAfs 2016-certainty of lifestyle shared
Afs 2016-certainty of lifestyle shared
 

Mehr von Redington

Diversity - Not Just a Gender Thing
Diversity - Not Just a Gender ThingDiversity - Not Just a Gender Thing
Diversity - Not Just a Gender ThingRedington
 
The Six Hardest Words in Pensions
The Six Hardest Words in PensionsThe Six Hardest Words in Pensions
The Six Hardest Words in PensionsRedington
 
25 Years at Gleneagles: Looking back & looking forward
25 Years at Gleneagles: Looking back & looking forward25 Years at Gleneagles: Looking back & looking forward
25 Years at Gleneagles: Looking back & looking forwardRedington
 
Technology and Investing - Where to from here?
Technology and Investing - Where to from here?Technology and Investing - Where to from here?
Technology and Investing - Where to from here?Redington
 
The Impact of Technology on the Pensions Industry
The Impact of Technology on the Pensions IndustryThe Impact of Technology on the Pensions Industry
The Impact of Technology on the Pensions IndustryRedington
 
21st Century Schemes – Deciding on the right scheme design for your members
21st Century Schemes – Deciding on the right scheme design for your members21st Century Schemes – Deciding on the right scheme design for your members
21st Century Schemes – Deciding on the right scheme design for your membersRedington
 
"Hi Alexa, how should I save for my pension?"
"Hi Alexa, how should I save for my pension?""Hi Alexa, how should I save for my pension?"
"Hi Alexa, how should I save for my pension?"Redington
 
Why we need to teach our children how to budget, save, invest and give back
Why we need to teach our children how to budget, save, invest and give backWhy we need to teach our children how to budget, save, invest and give back
Why we need to teach our children how to budget, save, invest and give backRedington
 
Making Decisions; An Effective Trustee Board
Making Decisions; An Effective Trustee BoardMaking Decisions; An Effective Trustee Board
Making Decisions; An Effective Trustee BoardRedington
 
Critical Friends - The Need for Straight Talking
Critical Friends - The Need for Straight TalkingCritical Friends - The Need for Straight Talking
Critical Friends - The Need for Straight TalkingRedington
 
DNC’s wake 1997 to 2016
DNC’s wake 1997 to 2016DNC’s wake 1997 to 2016
DNC’s wake 1997 to 2016Redington
 
Maybe there is an 'I' in team?
Maybe there is an 'I' in team?Maybe there is an 'I' in team?
Maybe there is an 'I' in team?Redington
 
Save your acorns book launch
Save your acorns   book launchSave your acorns   book launch
Save your acorns book launchRedington
 
Five steps to help your employees secure their financial futures
Five steps to help your employees secure their financial futuresFive steps to help your employees secure their financial futures
Five steps to help your employees secure their financial futuresRedington
 
Is Your Property Allocation RIght for You?
Is Your Property Allocation RIght for You?Is Your Property Allocation RIght for You?
Is Your Property Allocation RIght for You?Redington
 
Trend of overseas institutional investor asset allocation
Trend of overseas institutional investor asset allocationTrend of overseas institutional investor asset allocation
Trend of overseas institutional investor asset allocationRedington
 
Introduction and outlook of EU pension system
Introduction and outlook of EU pension systemIntroduction and outlook of EU pension system
Introduction and outlook of EU pension systemRedington
 
Challenges and opportunities for financial market globalisation
Challenges and opportunities for financial market globalisationChallenges and opportunities for financial market globalisation
Challenges and opportunities for financial market globalisationRedington
 
What role do consultants play in the value chain
What role do consultants play in the value chainWhat role do consultants play in the value chain
What role do consultants play in the value chainRedington
 
Summary of the key messages from the 2016 Annual Funding Statement
Summary of the key messages from the 2016 Annual Funding StatementSummary of the key messages from the 2016 Annual Funding Statement
Summary of the key messages from the 2016 Annual Funding StatementRedington
 

Mehr von Redington (20)

Diversity - Not Just a Gender Thing
Diversity - Not Just a Gender ThingDiversity - Not Just a Gender Thing
Diversity - Not Just a Gender Thing
 
The Six Hardest Words in Pensions
The Six Hardest Words in PensionsThe Six Hardest Words in Pensions
The Six Hardest Words in Pensions
 
25 Years at Gleneagles: Looking back & looking forward
25 Years at Gleneagles: Looking back & looking forward25 Years at Gleneagles: Looking back & looking forward
25 Years at Gleneagles: Looking back & looking forward
 
Technology and Investing - Where to from here?
Technology and Investing - Where to from here?Technology and Investing - Where to from here?
Technology and Investing - Where to from here?
 
The Impact of Technology on the Pensions Industry
The Impact of Technology on the Pensions IndustryThe Impact of Technology on the Pensions Industry
The Impact of Technology on the Pensions Industry
 
21st Century Schemes – Deciding on the right scheme design for your members
21st Century Schemes – Deciding on the right scheme design for your members21st Century Schemes – Deciding on the right scheme design for your members
21st Century Schemes – Deciding on the right scheme design for your members
 
"Hi Alexa, how should I save for my pension?"
"Hi Alexa, how should I save for my pension?""Hi Alexa, how should I save for my pension?"
"Hi Alexa, how should I save for my pension?"
 
Why we need to teach our children how to budget, save, invest and give back
Why we need to teach our children how to budget, save, invest and give backWhy we need to teach our children how to budget, save, invest and give back
Why we need to teach our children how to budget, save, invest and give back
 
Making Decisions; An Effective Trustee Board
Making Decisions; An Effective Trustee BoardMaking Decisions; An Effective Trustee Board
Making Decisions; An Effective Trustee Board
 
Critical Friends - The Need for Straight Talking
Critical Friends - The Need for Straight TalkingCritical Friends - The Need for Straight Talking
Critical Friends - The Need for Straight Talking
 
DNC’s wake 1997 to 2016
DNC’s wake 1997 to 2016DNC’s wake 1997 to 2016
DNC’s wake 1997 to 2016
 
Maybe there is an 'I' in team?
Maybe there is an 'I' in team?Maybe there is an 'I' in team?
Maybe there is an 'I' in team?
 
Save your acorns book launch
Save your acorns   book launchSave your acorns   book launch
Save your acorns book launch
 
Five steps to help your employees secure their financial futures
Five steps to help your employees secure their financial futuresFive steps to help your employees secure their financial futures
Five steps to help your employees secure their financial futures
 
Is Your Property Allocation RIght for You?
Is Your Property Allocation RIght for You?Is Your Property Allocation RIght for You?
Is Your Property Allocation RIght for You?
 
Trend of overseas institutional investor asset allocation
Trend of overseas institutional investor asset allocationTrend of overseas institutional investor asset allocation
Trend of overseas institutional investor asset allocation
 
Introduction and outlook of EU pension system
Introduction and outlook of EU pension systemIntroduction and outlook of EU pension system
Introduction and outlook of EU pension system
 
Challenges and opportunities for financial market globalisation
Challenges and opportunities for financial market globalisationChallenges and opportunities for financial market globalisation
Challenges and opportunities for financial market globalisation
 
What role do consultants play in the value chain
What role do consultants play in the value chainWhat role do consultants play in the value chain
What role do consultants play in the value chain
 
Summary of the key messages from the 2016 Annual Funding Statement
Summary of the key messages from the 2016 Annual Funding StatementSummary of the key messages from the 2016 Annual Funding Statement
Summary of the key messages from the 2016 Annual Funding Statement
 

Kürzlich hochgeladen

Kempen ' UK DB Endgame Paper Apr 24 final3.pdf
Kempen ' UK DB Endgame Paper Apr 24 final3.pdfKempen ' UK DB Endgame Paper Apr 24 final3.pdf
Kempen ' UK DB Endgame Paper Apr 24 final3.pdfHenry Tapper
 
Banking: Commercial and Central Banking.pptx
Banking: Commercial and Central Banking.pptxBanking: Commercial and Central Banking.pptx
Banking: Commercial and Central Banking.pptxANTHONYAKINYOSOYE1
 
Gender and caste discrimination in india
Gender and caste discrimination in indiaGender and caste discrimination in india
Gender and caste discrimination in indiavandanasingh01072003
 
Crypto Confidence Unlocked: AnyKYCaccount's Shortcut to Binance Verification
Crypto Confidence Unlocked: AnyKYCaccount's Shortcut to Binance VerificationCrypto Confidence Unlocked: AnyKYCaccount's Shortcut to Binance Verification
Crypto Confidence Unlocked: AnyKYCaccount's Shortcut to Binance VerificationAny kyc Account
 
Liquidity Decisions in Financial management
Liquidity Decisions in Financial managementLiquidity Decisions in Financial management
Liquidity Decisions in Financial managementshrutisingh143670
 
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshare
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshareAon-UK-DC-Pension-Tracker-Q1-2024. slideshare
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshareHenry Tapper
 
The Inspirational Story of Julio Herrera Velutini - Global Finance Leader
The Inspirational Story of Julio Herrera Velutini - Global Finance LeaderThe Inspirational Story of Julio Herrera Velutini - Global Finance Leader
The Inspirational Story of Julio Herrera Velutini - Global Finance LeaderArianna Varetto
 
10 QuickBooks Tips 2024 - Globus Finanza.pdf
10 QuickBooks Tips 2024 - Globus Finanza.pdf10 QuickBooks Tips 2024 - Globus Finanza.pdf
10 QuickBooks Tips 2024 - Globus Finanza.pdfglobusfinanza
 
What is sip and What are its Benefits in 2024
What is sip and What are its Benefits in 2024What is sip and What are its Benefits in 2024
What is sip and What are its Benefits in 2024prajwalgopocket
 
2024-04-09 - Pension Playpen roundtable - slides.pptx
2024-04-09 - Pension Playpen roundtable - slides.pptx2024-04-09 - Pension Playpen roundtable - slides.pptx
2024-04-09 - Pension Playpen roundtable - slides.pptxHenry Tapper
 
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptxOAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptxhiddenlevers
 
Introduction to Health Economics Dr. R. Kurinji Malar.pptx
Introduction to Health Economics Dr. R. Kurinji Malar.pptxIntroduction to Health Economics Dr. R. Kurinji Malar.pptx
Introduction to Health Economics Dr. R. Kurinji Malar.pptxDrRkurinjiMalarkurin
 
2B Nation-State.pptx contemporary world nation
2B  Nation-State.pptx contemporary world nation2B  Nation-State.pptx contemporary world nation
2B Nation-State.pptx contemporary world nationko9240888
 
ekthesi-trapeza-tis-ellados-gia-2023.pdf
ekthesi-trapeza-tis-ellados-gia-2023.pdfekthesi-trapeza-tis-ellados-gia-2023.pdf
ekthesi-trapeza-tis-ellados-gia-2023.pdfSteliosTheodorou4
 
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτοςΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτοςNewsroom8
 
Money Forward Integrated Report “Forward Map” 2024
Money Forward Integrated Report “Forward Map” 2024Money Forward Integrated Report “Forward Map” 2024
Money Forward Integrated Report “Forward Map” 2024Money Forward
 
Thoma Bravo Equity - Presentation Pension Fund
Thoma Bravo Equity - Presentation Pension FundThoma Bravo Equity - Presentation Pension Fund
Thoma Bravo Equity - Presentation Pension FundAshwinJey
 
Global Economic Outlook, 2024 - Scholaride Consulting
Global Economic Outlook, 2024 - Scholaride ConsultingGlobal Economic Outlook, 2024 - Scholaride Consulting
Global Economic Outlook, 2024 - Scholaride Consultingswastiknandyofficial
 
Building pressure? Rising rents, and what to expect in the future
Building pressure? Rising rents, and what to expect in the futureBuilding pressure? Rising rents, and what to expect in the future
Building pressure? Rising rents, and what to expect in the futureResolutionFoundation
 
Hello this ppt is about seminar final project
Hello this ppt is about seminar final projectHello this ppt is about seminar final project
Hello this ppt is about seminar final projectninnasirsi
 

Kürzlich hochgeladen (20)

Kempen ' UK DB Endgame Paper Apr 24 final3.pdf
Kempen ' UK DB Endgame Paper Apr 24 final3.pdfKempen ' UK DB Endgame Paper Apr 24 final3.pdf
Kempen ' UK DB Endgame Paper Apr 24 final3.pdf
 
Banking: Commercial and Central Banking.pptx
Banking: Commercial and Central Banking.pptxBanking: Commercial and Central Banking.pptx
Banking: Commercial and Central Banking.pptx
 
Gender and caste discrimination in india
Gender and caste discrimination in indiaGender and caste discrimination in india
Gender and caste discrimination in india
 
Crypto Confidence Unlocked: AnyKYCaccount's Shortcut to Binance Verification
Crypto Confidence Unlocked: AnyKYCaccount's Shortcut to Binance VerificationCrypto Confidence Unlocked: AnyKYCaccount's Shortcut to Binance Verification
Crypto Confidence Unlocked: AnyKYCaccount's Shortcut to Binance Verification
 
Liquidity Decisions in Financial management
Liquidity Decisions in Financial managementLiquidity Decisions in Financial management
Liquidity Decisions in Financial management
 
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshare
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshareAon-UK-DC-Pension-Tracker-Q1-2024. slideshare
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshare
 
The Inspirational Story of Julio Herrera Velutini - Global Finance Leader
The Inspirational Story of Julio Herrera Velutini - Global Finance LeaderThe Inspirational Story of Julio Herrera Velutini - Global Finance Leader
The Inspirational Story of Julio Herrera Velutini - Global Finance Leader
 
10 QuickBooks Tips 2024 - Globus Finanza.pdf
10 QuickBooks Tips 2024 - Globus Finanza.pdf10 QuickBooks Tips 2024 - Globus Finanza.pdf
10 QuickBooks Tips 2024 - Globus Finanza.pdf
 
What is sip and What are its Benefits in 2024
What is sip and What are its Benefits in 2024What is sip and What are its Benefits in 2024
What is sip and What are its Benefits in 2024
 
2024-04-09 - Pension Playpen roundtable - slides.pptx
2024-04-09 - Pension Playpen roundtable - slides.pptx2024-04-09 - Pension Playpen roundtable - slides.pptx
2024-04-09 - Pension Playpen roundtable - slides.pptx
 
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptxOAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
 
Introduction to Health Economics Dr. R. Kurinji Malar.pptx
Introduction to Health Economics Dr. R. Kurinji Malar.pptxIntroduction to Health Economics Dr. R. Kurinji Malar.pptx
Introduction to Health Economics Dr. R. Kurinji Malar.pptx
 
2B Nation-State.pptx contemporary world nation
2B  Nation-State.pptx contemporary world nation2B  Nation-State.pptx contemporary world nation
2B Nation-State.pptx contemporary world nation
 
ekthesi-trapeza-tis-ellados-gia-2023.pdf
ekthesi-trapeza-tis-ellados-gia-2023.pdfekthesi-trapeza-tis-ellados-gia-2023.pdf
ekthesi-trapeza-tis-ellados-gia-2023.pdf
 
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτοςΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
 
Money Forward Integrated Report “Forward Map” 2024
Money Forward Integrated Report “Forward Map” 2024Money Forward Integrated Report “Forward Map” 2024
Money Forward Integrated Report “Forward Map” 2024
 
Thoma Bravo Equity - Presentation Pension Fund
Thoma Bravo Equity - Presentation Pension FundThoma Bravo Equity - Presentation Pension Fund
Thoma Bravo Equity - Presentation Pension Fund
 
Global Economic Outlook, 2024 - Scholaride Consulting
Global Economic Outlook, 2024 - Scholaride ConsultingGlobal Economic Outlook, 2024 - Scholaride Consulting
Global Economic Outlook, 2024 - Scholaride Consulting
 
Building pressure? Rising rents, and what to expect in the future
Building pressure? Rising rents, and what to expect in the futureBuilding pressure? Rising rents, and what to expect in the future
Building pressure? Rising rents, and what to expect in the future
 
Hello this ppt is about seminar final project
Hello this ppt is about seminar final projectHello this ppt is about seminar final project
Hello this ppt is about seminar final project
 

Living Longer At What Price- Mortality Modelling

  • 1. 8th July 2008 Living Longer – At What Price? Mortality Modelling
  • 2. Contents Mortality Modelling Contents Deterministic Mortality Models Deterministic Models 3 Stochastic Mortality Models Why Stochastic Models? 6 Stochastic Mortality Models 9 Application Procedure and Model Comparison 15 Appendix 22 2 “Where there is a considerable range of possible outcomes, the FSA expects firms to use stochastic techniques to evaluate these risks. In time, for example, longevity risk, where this constitutes a significant risk for the firm, may fall into this category.” -----FSA’s Regulatory Guidance for Actuaries
  • 4. Mortality Modelling Deterministic Projections Scenario Tests with Different Deterministic Mortality Tables  Different mortality assumptions imply different pension benefit cash flow structures for a specific pension scheme.  This research compares the impact on a specific pension scheme’s cash flows, presents value and duration of ten deterministic mortality projections produced by the CMI, including the original “92” Series projection, cohort projections and cohort projection with 1% and 2% underpins. 4
  • 5.  The table below shows that a change in mortality assumptions can have a big impact on the PV and Duration of a pension scheme’s benefits. *E.g. The PV for this specific scheme (calculated with a long cohort / 2% underpin mortality table) is 13% larger than the PV calculated with “92” table, and the duration increases by 13.5%. Scenario Tests with Different Deterministic Mortality Tables Active Deferred Pensioners Total PV (£ million) Duration (year) PV (£ million) Duration (year) PV (£ million) Duration (year) PV (£ million) Duration (year) "92" 195 26.8 195 25.5 598 11.1 988 17.0 SC 196 26.9 197 25.6 605 11.2 998 17.1 SC 1% 201 27.5 201 26.1 613 11.4 1,015 17.5 SC 2% 216 29.3 218 27.8 641 12.3 1,075 18.9 MC 200 27.2 201 25.9 619 11.4 1,020 17.4 MC 1% 204 27.8 205 26.4 626 11.6 1,035 17.7 MC 2% 218 29.4 220 27.9 648 12.4 1,086 18.9 LC 209 28.0 210 26.6 648 12.0 1,067 18.0 LC 1% 212 28.5 214 27.1 652 12.2 1,078 18.3 LC 2% 223 29.8 225 28.3 666 12.7 1,115 19.3 5 Accounting basis TPR new proposal Mortality Modelling Deterministic Projections
  • 6. Mortality Modelling Why Stochastic Models? Projection vs. Experience : How projections can go wrong (CMI Lee-Carter Projection) Source: CMI Male Assured Lives 6  By using Male Assured Lives data from 1947 to 1980 to project the future mortality rate from 1980 to 2004 at age 65.  The graph shows that, by the end of 2004, the projected probability of death for males aged 65 is about 0.015, but the realised mortality rate is about 0.009 - which is much lower than predicted.  What is worse is that projections continually overestimate the probability of death over the estimation period; in other words, they underestimate the life expectancy substantially.
  • 7. Graduation: Smoothing Raw Data to Remove Random Fluctuation Source: CMI Male Assured Lives 1947-2005 Raw Death Rate Graduated Death Rate In order to calculate the PV of liabilities, an actuarial valuation requires best estimate mortality rates as a starting point, even if a prudent margin is being added, to evaluate liability present values; these will be an instruction to set contribution rate as well. But we will never know when mortality experience will go wrong and how far it may be from the “so-called” best estimates. These best estimates are based on “smoothed” results - which means the randomness in mortality is largely ignored. 7 Mortality Modelling Why Stochastic Models
  • 8. Stochastic Projections: Allow for randomness in mortality rates Can estimate Longevity Value at Risk (LVaR) •Monte-Carlo Simulation: Can show the whole range of possible future mortality rates •Probability of each scenario •Full distribution of future pension liabilities Deterministic Projections: Assume fixed mortality rates Scenario Tests: Cannot determine the probability of a specific scenario •Single Value of Liability: Does not include all scenarios • Does not show full distribution of possible future mortality rates Compare Deterministic and Stochastic Mortality Models 8 Mortality Modelling Why Stochastic Models
  • 10. Mortality Modelling Stochastic Mortality Models Eight Stochastic Mortality Models 10 Details of model specifications are described in Redington Longevity Technical paper, which is available upon request. All models capture the age and period effects but they vary in the modelling approach. Lee-Carter extension, APC, Three factor CBD, Three-factor CBD extension and Four-Factor CBD capture the cohort effect in the model. (2, 6, 7 and 8) 1 2 3 4 5 6 7 8
  • 11. Two Major Model Families  CBD Models: The Cairns, Blake and Dowd (CBD) model was developed by three professors in the UK: Professor David Blake from Cass Business School, Professor Andrew Cairns from Heriot- Watt University and Professor Kevin Dowd from Nottingham University Business School. The CBD model was developed for and tested using mortality data from males living in England and Wales, and has yet to be tested with data from any other countries. However, the model has already been taken up widely by actuaries in Germany and is currently being investigated by the CMI (Pension Institute, 2007).  Lee Carter Models: The Lee-Carter model was developed by Professors Ronald Lee and Lawrence Carter. This model has become the “leading statistical model of mortality forecasting in the demographic literature” in the United States (Deaton and Paxson, 2004). Lee and Carter originally calibrated their model to use United States mortality data from 1933- 1987. Girosi and King (2007) note that the model is “now being applied to all-cause and cause- specific mortality data from many countries and time periods, and all well beyond the application for which it was designed” (Girosi and King, 2007). 11 Mortality Modelling Stochastic Mortality Models
  • 12. Two Major Model Families  Four models from the two major model families, the CBD and Lee-Carter, were tested.  Lee Carter Model: A simple one-factor model that assumes mortality improvement for different ages has a perfect correlation. As a result, the model gives less flexibility in age specific volatilities and usually projects less volatile future mortality rates.  CBD Model: Accounts for more factors to allow different improvements across different ages at different periods of time. As a result, the model gives more flexibility in age specific volatilities and often projects more volatile future mortality rates than Lee Carter model. 12 Mortality Modelling Stochastic Mortality Models
  • 13. Data Sample:  The data used in testing the four models was taken from the Human Mortality Database (HMD).  In order to analyse the models’ sensitivities to the choice of data sample, models were calibrated and tested against two samples:  The first sample included population mortality data for ages 20 to 100 from 1920 to 1960;  The second test included population mortality data for ages 20 to 100 from 1963 to 1983;  The figures below show mortality rate data in the first sample is more volatile than the mortality rate data in the second sample. 13 Mortality Modelling Stochastic Mortality Models
  • 14. Summary of Statistical Tests Statistical tests: MSE, Sign and Outlier Test • MSE and Sign Test show that the forecasting accuracy of CBD family models is more sensitive to the choice of sample than Lee Carter family. • The Outlier test shows that both of the models fail to capture the “hump” effect for younger ages, and the Lee-Carter models also systematically over-estimated the mortality rates for old ages and failed to project a proper confidence interval for old ages statistically. Conclusion The Two-Factor CBD model is the most appropriate model for longevity risk analysis and management purpose, because it:  Produces stabler projections of future mortality rates;  Produces confidence intervals that cover most realised mortality rates, especially for older ages;  Is easy to implement. 14 Mortality Modelling Stochastic Mortality Models
  • 15. Mortality Modelling Application of Stochastic Mortality Models 15
  • 16. Application Procedures Evaluate possible solutions Manage longevity risk in the overall LDI strategy Quantify longevity risk Estimate benefit cash flows with simulated mortality rates Generate simulations on future mortality rates with calibrated model Calibrate mortality model with historical data 16 Mortality Modelling Applications
  • 17. Stochastic Simulations – Mortality Rate • By calibrating stochastic mortality models with historical data, a large number of simulated mortality tables can be generated (e.g. 1000 tables). • These simulated mortality tables provide a range of possible future mortality rates by incorporating age, period and cohort effects. • The two graphs below show the range of mortality rate simulations and a comparison with the realised mortality rate during that period. 17 Mortality Modelling Applications
  • 18. Stochastic Cash Flows For a better understanding of pension liability, cashflow analysis is largely adopted:  By using the simulated future mortality rates from previous simulations, the cashflow structure of a generic pension scheme is projected for 1000 times.  By doing this, we can observe a range of possible cash flows implied by the two models.  This forms the basis of quantifying longevity risk for a specific pension scheme. CBD Model Lee Carter Model 18 Mortality Modelling Applications
  • 19.  The cashflow structures are then discounted with a flat discount curve. The two graphs below show the distribution of pension liabilities under the different projections of the two models.  CBD Model: Predicts a smoother and more spread out distribution of liabilities. This means more longevity risk on the tails.  Lee Carter Model: Predicts a tighter distribution of pension liabilities. This means less longevity risk on the tails. Model Comparison - Distributions 19 Mortality Modelling Applications
  • 20. Model Comparison – Main Statistics Two- Factor CBD Model Lee Carter Model Two-Factor CBD Model PV Lee-Carter Model PV Short cohort Medium cohort Long cohort (£’000,000) (£’000,000) (£’000,000) (£’000,000) (£’000,000) Mean 1,002 998 998 1,020 1,067 S.d. 32 16 n/a n/a n/a 95% 1,054 1,026 n/a n/a n/a 5% 954 973 n/a n/a n/a VaLR 52 27 n/a n/a n/a As % of Total Liability 5.17% 2.73% n/a n/a n/a 20 Mortality Modelling Applications
  • 21. Contacts Dawid Konotey-Ahulu | Partner Direct: +44 (0) 207 250 3415 dawid@redingtonpartners.com Robert Gardner | Partner Direct: +44 (0) 207 250 3416 robert.gardner@redingtonpartners.com Redington Partners LLP 13 -15 Mallow Street London EC1Y 8RD Telephone: +44 (0) 207 250 3331 www.redingtonpartners.com THE DESTINATION FOR ASSET & LIABILITY MANAGEMENT Contacts Disclaimer Disclaimer For professional investors only. Not suitable for private customers. The information herein was obtained from various sources. We do not guarantee every aspect of its accuracy. The information is for your private information and is for discussion purposes only. A variety of market factors and assumptions may affect this analysis, and this analysis does not reflect all possible loss scenarios. There is no certainty that the parameters and assumptions used in this analysis can be duplicated with actual trades. Any historical exchange rates, interest rates or other reference rates or prices which appear above are not necessarily indicative of future exchange rates, interest rates, or other reference rates or prices. Neither the information, recommendations or opinions expressed herein constitutes an offer to buy or sell any securities, futures, options, or investment products on your behalf. Unless otherwise stated, any pricing information in this message is indicative only, is subject to change and is not an offer to transact. Where relevant, the price quoted is exclusive of tax and delivery costs. Any reference to the terms of executed transactions should be treated as preliminary and subject to further due diligence . Please note, the accurate calculation of the liability profile used as the basis for implementing any capital markets transactions is the sole responsibility of the Trustees' actuarial advisors. Redington Partners will estimate the liabilities if required but will not be held responsible for any loss or damage howsoever sustained as a result of inaccuracies in that estimation. Additionally, the client recognizes that Redington Partners does not owe any party a duty of care in this respect. Redington Partners are investment consultants regulated by the Financial Services Authority. We do not advise on all implications of the transactions described herein. This information is for discussion purposes and prior to undertaking any trade, you should also discuss with your professional tax, accounting and / or other relevant advisers how such particular trade(s) affect you. All analysis (whether in respect of tax, accounting, law or of any other nature), should be treated as illustrative only and not relied upon as accurate. 21
  • 22. Appendix Model Testing Evaluation Criteria  Mean Squared Error (MSE) MSE is used to test the forecasting accuracy of the models defined as: Where T is the total number of projected years, and are respectively the projected and actual observation for age x at time i. The smaller the test statistic is the more accurate the projection is.  Sign Test Sign test is used to test the hypothesis that the model residuals are unbiased. Mathematically, if m is the number of positive residuals, then m should follow a binomial distribution with parameters being the number of residuals (n) and 0.5. For test here, normal approximation is used.  Outlier Test The outliers test is used to study the model’s capability to project confidence intervals which can cover most of the realized mortality rates as expected. For example, a 90% confidence interval is expected to cover 90% of the observation points. 22
  • 23. MSE and Sign Test  MSE test shows that, in the 40 year data sample, the Lee-Carter model provides the best projection accuracy; however, in the 20 year data sample, the CBD models performed better than the Lee Carter models, while the three-factor CBD model provided the most accurate results.  Comparing the sign test results reveals that nearly all models based on two datasets predict biased mortality rates; this is because the sign test statistics are all significantly larger than the critical value of 1.96. The exception is the three-factor CBD model in the 40 year sample data test.  In general, the two tests show that the forecasting accuracy for CBD family models is more sensitive to the choice of sample than Lee Carter family. MSE test statistics show that the CBD models can produce a better projection if the end-user properly selects the sample space. 23 Appendix Model Testing
  • 24. Outliers Test  The tables above show that, for both projection periods, the number of outliers is greater than expected. The exception is the two-factor CBD model, which produced significantly less outliers than expected. 24 Appendix Model Testing
  • 25. Outliers Test  The orange area represents outlier in right hand tail; the red area represents outlier in left hand tail, and the green area represents observations that are within the confidence interval.  The test results show that both of the models failed to capture the “hump” effect for younger ages. The Lee-Carter models also systematically over-estimated the mortality rates for old ages and failed to project a proper confidence interval for old ages. CBD ModelLee Carter Model 25 Appendix Model Testing